A Phase I/II, Multicentre, Open-label Study of MAK683 in Adult Patients With Advanced Malignancies
The purpose of this Phase I/II study is to establish the maximum tolerated dose (MTD) and/or
recommended phase 2 dose (RP2D) and to evaluate the safety, antitumour activity and
pharmacokinetic (PK) profile of MAK683 in patients with advanced malignancies such as
Diffuse Large B cell Lymphoma (DLBCL), nasopharyngeal carcinoma (NPC) or other advanced
solid tumours for whom no further effective standard treatment is available.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society